Oregon Health and Science University
Open enrollment across a mixed-phase pipeline
According to ClinicalTrials.gov-derived indexes, Oregon Health and Science University sits in the top decile of US sponsors by registered trial count (#67 of 15,742 sponsors by registered trial count).
Oregon Health and Science University: 546 sponsored US clinical trials, 91 recruiting.
Oregon Health and Science University sponsors 546 registered US clinical trials on ClinicalTrials.gov, 91 of them currently recruiting, and 370 completed. 73 of these trials are in Phase 3-4 (later-stage) and 92 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Obesity, with 6 trials.
Top-decile sponsor footprint
Oregon Health and Science University ranks in the top decile of sponsors by registered trial count (#67 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
370 of 420 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (88.1%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
546 total, page 9 of 11
Lipoic Acid as a Treatment for Acute Optic Neuritis
NCT01294176
Sterol and Isoprenoid Disease Research Consortium: Smith-Lemli-Opitz Syndrome
NCT01356420
The Effect of Nitroprusside on Intrauterine Device (IUD) Insertion
NCT01248091
Effects of Stress-reducing Aromatherapy
NCT01307748
Physiological Responses in Tobacco Chippers
NCT01237834
Care Transitions Innovation (C-TraIn)
NCT01906645
Pediatric Appendicitis Pathway Study
NCT01192620
Lipoic Acid and Omega-3 Fatty Acids for Alzheimer's Disease
NCT01058941
Exercise Information for Women With Cancer
NCT03120819
Safety & Health Improvement: Enhancing Law Enforcement Departments
NCT01279941
The Multi-Sensor Distance Accuracy Study
NCT02241993
Vitamin E Treatment for Long-Chain 3-Hydroxyacyl Coenzyme A (CoA) Dehydrogenase (LCHAD) Associated Neuropathy
NCT00840112
Comparison of Doubled Quadrupled Versus Quadrupled Allograft Tissue Constructs for Anterior Cruciate Ligament (ACL) Reconstruction
NCT01148784
Group Eczema Education Visits:Impact on Patient and Family Quality of Life
NCT01143012
Examining Bladder Control Using Magnetic Resonance Imaging (MRI) and Diffusion Tensor Imaging (DTI)
NCT01110278
Paracervical Block for Pain Control in First Trimester Abortion
NCT01094366
Topical Timolol 0.5% Solution for Proliferating Infantile Hemangiomas
NCT01147601
Efficacy of Tart Cherry Juice to Reduce Pain and Inflammation Among Patients With Inflammatory Osteoarthritis
NCT01073982
Spironolactone in Adult Congenital Heart Disease
NCT01069510
Frozen Red Blood Cell Transfusions in Trauma Patients
NCT01038557
Exercising Together: An Intervention for Prostate Cancer Survivors and Spouses
NCT00954044
Effect of Continuous Positive Airway Pressure (CPAP) on Lower Esophageal Sphincter Pressure in Morbidly Obese Patients
NCT01099735
Apremilast in the Treatment of Uveitis
NCT00889421
Melatonin Studies of Totally Blind Children
NCT00795236
Development of an Instrumented System to Measure Mobility in Parkinson's Disease
NCT01174758
Clinical Evaluation of the Storz CMAC Laryngoscope
NCT00956592
Yoga for Fibromyalgia
NCT00966732
Preterm Neonatal Feeding Protocol Comparing Feed Administration Time
NCT00997854
Thrombelastography Based Dosing of Enoxaparin
NCT00990236
Nurse Family Partnership (NFP) Contraceptive Study
NCT00928538
Oral Contraceptives and Body Mass Index
NCT01170390
The Effect of a Non-hormonal Cox-2 Inhibitor (Celebrex) on Ovulation
NCT01129245
Comparison of Two Types of Ankle Braces in the Management of Ankle Pain in Hemophilia
NCT00972296
Sevoflurane as an Anesthetic During Dilation and Evacuation Procedures
NCT01048658
Initial Test of the Time to Talk CARDIO (Creating a Real Dialogue In the Office) Program
NCT00983333
Quantification of the Antidyskinetic Effect of Amantadine and Topiramate in Parkinson's Disease
NCT00794313
Effect of Nitrous Oxide (N2O) on Intraocular Pressure in Healthy Volunteers
NCT00967694
Medical Therapy Versus Sinus Surgery for Chronic Rhinosinusitis: A Prospective, Multi-institutional Study
NCT01255566
Pregnancy-Related Low Back Pain and Complementary and Alternative Medicine (CAM) Treatment
NCT00937365
Damage Control for Duodenal and Combined Duodenal-Pancreatic Injuries
NCT00937118
The Physical Effects of Pain Catastrophizing in Labor
NCT01012466
Prospective Evaluation of Forceplate Measured Levodopa-Induced Dyskinesia
NCT00912977
Causes and Circumstances of Horse Related Injuries and Impact on Quality of Life
NCT00935428
An Evaluation of Actigraphy as an Indicator of Sleep and Wake in Children
NCT00928993
Leak Pressure of Uncuffed Pediatric Endotracheal Tubes
NCT00968058
Creating African-American Wellness Through Exercise
NCT00867776
Prevention of Neurosurgical Wound Infections
NCT00915967
Pulp Capping With Two Different Agents
NCT00812877
High and Low Dose Carbidopa Treatment of Parkinson's Disease
NCT01399905
Testing of the Apnea Prevention Device
NCT00875134
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 52 |
| Phase 2 | 40 |
| Phase 3 | 6 |
| Phase 4 | 67 |
Therapeutic Areas
What is open in the Oregon Health and Science University pipeline
91 recruiting of 546 indexed (17% open); 370 completed (68%).
Phase mix: 73 late (III/IV) vs 92 early (I/II) (balanced across stages).
Top condition: Obesity (6 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Oregon Health and Science University: open-pipeline peers nationwide
Peers matched on 546 registered trials and 17% open enrollment, not the therapeutic-area sidebar.
Oregon Health and Science University sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 546 trials (± recruiting share)
- Ohio State University · 552 trials · 21% recruiting
- Amgen · 558 trials · 10% recruiting
- Merck Sharp & Dohme · 558 trials · 22% recruiting
- Virginia Commonwealth University · 558 trials · 14% recruiting
Sponsors near 17% open enrollment (± trial volume)
- Adagene · 17% recruiting · 6 trials
- Agendia · 17% recruiting · 6 trials
- Akamis Bio · 17% recruiting · 6 trials
- Angiodynamics · 17% recruiting · 12 trials
Related
What to do with this Oregon Health and Science University page
546 registered trials is a research-attention snapshot, not an endorsement of Oregon Health and Science University or any single study.
- 91 of Oregon Health and Science University's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Obesity is the condition Oregon Health and Science University studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Obesity trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Oregon Health and Science University pipeline card: 546 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.